Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Geron CorpGERN-13.4091.429.27-9.45-69.03%79.39%51.42$4.01$11.28105,792$4.07

Detail of Geron Corp

 
CEO
Dr. John A. Scarlett M.D.
Employees
98
Industry
Biotechnology
Sector
Healthcare
Market cap
$3B

Company details

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
NI
Revenue (Rev)
$29.48M
Cost of goods (CoG)
-$473,000.00
Gross profit (GP)
$28.68M
Operating expense (OE)
-$236.98M
Research and development (R&D)
-$113.22M
General and administrative (G&A)
-$123.76M
Operating income (OI)
-$207.97M
Other income expense (OIE)
-$147,000.00
Pretax income (PI)
-$201.19M
Net income (NI)
-$201.19M
Geron Corp
GERN • XNGS • US
$4.07
+2.11 (107.65%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.30
Margin profit
0.00%
52 week low
$1.75
52 week high
$5.09
50-day simple moving average
$3.92
200-day simple moving average
$4.01
Percent held by insiders
0.09%
Percent held by institutions
85.34%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
GERN +104.52%
eps change
GERN 0.00%